In the 35 PD-L1 positive ESCC patients, ORR was 20.0% (95% CI: 8.0–37.0) and duration of response (DOR) varied from 4.2 to 25.1+ months, with 14.3% (5/35) patients being effective for over 6 months and 8.6% (3/35) patients having responses more than 12 months. The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.